Adapting to Disruption of Pragmatic Clinical Trials Studying Nonpharmacological Approaches to Pain Management during the COVID-19 Pandemic: Lessons Learned from the NIH-DOD-VA Pain Management Collaboratory

Brian C. Coleman, DC
VA Connecticut Healthcare System & Yale University
VA HSR&D Spotlight on Pain Management
November 3, 2020
Acknowledgements

• The lead funding organizations of the PMC and PMC3 include the National Center for Complementary and Integrative Health (NCCIH) of the National Institutes of Health (NIH), the Department of Defense (DOD), and the Department of Veterans Affairs (VA). An additional seven NIH institutes, centers and program offices serve as co-sponsors of the pragmatic clinical trials.

• The research reported in this presentation was supported by the National Center for Complementary and Integrative Health of the National Institutes of Health under award number U24AT009769.

• This work is a product of the NIH-DOD-VA Pain Management Collaboratory. The contents of this presentation are the sole responsibility of the authors and do not necessarily reflect the views, opinions or policies of the National Institutes of Health, the Department of Veterans Affairs Health Services Research and Development Service, Uniformed Services University of the Health Sciences, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., the Department of Defense, the Departments of the Army, Navy, or Air Force. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government.

For more information: www.painmanagementcollaboratory.org
Adapting to disruption of research during the COVID-19 pandemic while testing nonpharmacological approaches to pain management

Brian C. Coleman, Jacob Kean, Cynthia A. Brandt, Peter Peduzzi, Robert D. Kerns on behalf of the NIH-DoD-VA Pain Management Collaboratory

Available (Open Access) from: https://academic.oup.com/tbm/article/10/4/827/5901420
Outline

• Changes in the Management of Pain

• Introduction to the NIH-DOD-VA Pain Management Collaboratory (PMC)

• Pain Management Collaboratory Coordinating Center Response to the COVID-19 Pandemic

• Effects of COVID-19 Pandemic on PMC Pragmatic Clinical Trials

• Lessons Learned and Moving Forward
Gap between Evidence and Practice

• Growing evidence to support integrated, coordinated, multimodal and interdisciplinary models of pain care that support patient activation and pain self-management

• Significant organizational/systems, provider and patient-level barriers to timely and equitable access to these approaches

• Veteran and Military health systems are ideally positioned to address this gap as learning health systems
A Shift in Pain Management

- Primary use of evidence-based, nonpharmacological approaches

Models of Integrated Pain Care (VA & DOD)

Whole Health

- **EMPOWER**
  - Exploring What Matters Most
  - Partners with Veterans
  - Personal Health Plan

- **EQUIP**
  - Self-Care Providers
  - Well-being Programs
  - Health Coaching

- **TREAT**
  - Clinical Care
  - Whole Health Clinicians
  - Health and disease management within a Whole Health paradigm

### Patient Aligned Care Team (PACT) in Primary Care
- Routine screening for presence & severity of pain
- Assessment and management of common pain conditions
- Support from MH-PC Integration; OEF/IF, & Post-Deployment Teams; Expanded care management
- Pharmacy Pain Care Clinics; Pain Schools; CAM integration

### Patient/Family Education and Self Care
- Understand BPS model; Nutrition/weight mgmt.
- Exercise/conditioning, & sufficient sleep
- Mindfulness meditation/relaxation techniques
- Engagement in meaningful activities
- Family & social support
- Safe environment/surroundings

### Secondary Consultation
- Multidisciplinary Pain Medicine Specialty Teams
- Rehabilitation Medicine
- Behavioral Pain Management; Mental Health/SUD Programs

### Tertiary, Interdisciplinary Pain Centers
- Advanced pain medicine diagnostics & interventions
- CARF accredited pain rehabilitation

### VA-DoD Stepped Care Pain Care
- RISK
- Comorbidities
- Treatment Refractory
- Complexity
Pain Management Collaboratory (PMC)

• Investment of $81 million over 6 years from collaborative sponsorship efforts from:
  • National Institutes of Health
    • National Center for Complementary and Integrative Health, National Institute for Neurological Disorders and Stroke, National Institute of Drug Abuse, National Institute of Alcohol Abuse and Alcoholism, National Institute of Child Health and Human Development, National Institute of Nursing Research, Office of Behavioral and Social Sciences Research, Office of Research on Women’s Health
  • Department of Defense
    • Clinical Rehabilitative Medicine Research Program, Military Operational Medicine Research Program
  • Department of Veterans Affairs
    • Health Services Research & Development Service, Office of Research and Development
Pain Management Collaboratory (PMC)

• Key Objective
  • Conduct pragmatic clinical trials to evaluate whether nonpharmacological approaches for management of pain and innovative care models are effective when delivered in the Veterans Health Administration (VHA) and/or the Defense Health Agency (DHA)

• General Structure
  • 11 phased (UH3 planning + UG3 implementation) pragmatic clinical trials
  • Support from a centralized Coordinating Center (PMC³)
  • Work closely with a Steering Committee, External Board, and Patient Resource Group
<table>
<thead>
<tr>
<th>Study Title</th>
<th>Investigators</th>
<th>Funding Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chiropractic Care for Veterans: A Pragmatic Randomized Trial Addressing Dose Effects for cLBP</td>
<td>C. Goertz/C. Long</td>
<td>NIH</td>
</tr>
<tr>
<td>Cooperative Pain Education and Self-management: Expanding Treatment for Real-world Access (COPES ExTRA)</td>
<td>A. Heapy</td>
<td>NIH</td>
</tr>
<tr>
<td>Engaging Veterans Seeking Service-Connection Payments in Pain Treatment</td>
<td>M. Rosen/S. Martino</td>
<td>NIH</td>
</tr>
<tr>
<td>Improving Veteran Access To Integrated Management of Chronic Back Pain</td>
<td>S. George/S.N. Hastings</td>
<td>NIH</td>
</tr>
<tr>
<td>Complementary and Integrative Health for Pain in the VA: A National Demonstration Project</td>
<td>S. Taylor/S. Zeliadt</td>
<td>VA</td>
</tr>
<tr>
<td>Resolving the Burden of Low Back Pain in Military Service Members and Veterans</td>
<td>S. Farrokhi/C. Dearth/E. Russell</td>
<td>DOD</td>
</tr>
<tr>
<td>SMART Stepped Care Management for Low Back Pain in Military Health System</td>
<td>J. Fritz/D. Rhon</td>
<td>NIH</td>
</tr>
<tr>
<td>Resolving the Burden of Low Back Pain in Military Service Members and Veterans</td>
<td>D. McGeary/J. Goodie</td>
<td>DOD</td>
</tr>
<tr>
<td>Testing Two, Scalable, Veteran-Centric Mindfulness Based Interventions for Chronic Musculoskeletal Pain: A Pragmatic, Multisite Trial</td>
<td>D. Burgess</td>
<td>DOD</td>
</tr>
<tr>
<td>Ultrasound-Guided Percutaneous Peripheral Nerve Stimulation: A Non-Pharmacological Alternative for the Treatment of Postoperative Pain</td>
<td>B. Ilfeld</td>
<td>DOD</td>
</tr>
<tr>
<td>Implementation of a Pragmatic Trial of Whole Health Team vs. Primary Care Group Education to Promote Non-Pharmacological Strategies to Improve Pain, Functioning, and Quality of Life in Veterans</td>
<td>K. Seal/W. Becker</td>
<td>NIH</td>
</tr>
</tbody>
</table>
Pain Management Collaboratory Coordinating Center (PMC³)

• **Purpose**
  - Provide national leadership and strategic direction for the PMC program for internal and external stakeholders
  - Support and enable the PCTs to conduct efficient, large-scale trials
  - Development and refinement of innovative tools, best practices, and other resources in the conduct of high impact pragmatic clinical trials
PMC Trials – Pragmatic Design

• What is a pragmatic trial?
  • Trials designed to show the real-world effectiveness of the intervention in broad patient groups embedded in clinical practice setting

• Why pragmatic studies?
  • Emphasize generalizability of results and protect rigor
  • Results may inform VHA, DHA, and other health care systems about nonpharmacological treatments for pain management
Pre-February, 2020 – “Business as Usual”

- Most trials transitioning between planning and implementation phases
  - Few already beginning recruitment for implementation phase
  - Few wrapping up planning pilot studies

- Many trials working with study teams and PMC³ resources to finalize plans with study sites for full-scale, implementation trial
March, 2020 – COVID-19

• PMC³ and PMC recognizes the potential challenge of the COVID-19 Pandemic to ongoing PCTs
  • Aggressive development and enactment of a plan-of-action to address key issues
  • Need for response and plan-of-action by PCTs to adapt appropriately
  • Open dialogue between PCT PIs and PMC³ Directors, representatives from sponsoring agencies
  • Need for tracking of impacts and responses to identify opportunities for reflection and for sharing with scientific community
PMCC Response to COVID-19

• PMC Work Groups

• COVID-19 Challenges Tracking Tool

• COVID-19 Impact on Pain Outcomes
A Vehicle of Communication - The PMC Work Groups

• Although the PMC is a large, mainly decentralized effort, our culture emphasizes
  • Good communication
  • Collaborative, congenial relationships
  • Cross-collaboratory standards

• PMC work groups at the heart of this culture
  • Common link between PCTs and PMC

• Recognized the need for a mechanism of rapidly and efficiently communicating and documenting changes in SOP due to COVID-19
  • Use the domain-focused work groups
PMC COVID-19 Challenges Tracking Tool

• Spreadsheet used to track multiple domains and characterize impact of COVID-19 on PCT operations
  • Project Managers → PMC³ Leadership
  • Frequent review with stakeholders across the PMC

• Organized into specific domains:
  • Intervention delivery
  • Regulatory approval
  • Data collection
  • Study recruitment
  • Trial integrity
  • Statistical analyses
  • Clinical outcomes
  • Clinical outcomes

• Tasks assigned to other work groups or members of PMC³ as appropriate
<table>
<thead>
<tr>
<th>Number</th>
<th>Identification Date</th>
<th>WG</th>
<th>Domain</th>
<th>Issue</th>
<th>Follow-up</th>
<th>Action Item (Yes/No)</th>
<th>Action Assigned To</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2020.03.26</td>
<td>Ethics &amp; Reg</td>
<td>Intervention Delivery</td>
<td>1) What platforms are approved for use for virtual groups or delivery of remote interventions? 2) There is a need for real-time sharing of this information. We want to not only find solutions for our current situation, but also want to be able to add to the literature for delivering interventions remotely.</td>
<td>2020.4.23 update: UniversityMIN Zoom has been approved by VA CIB for use with DIPRS. VA is potentially allowing Cisco web ex and Microsoft Teams. DoD is potentially allowing Adobe Connect. VA sites have been successful with VA Video Connect (VVC) in research.</td>
<td>Yes</td>
<td>EHR</td>
<td>MIKE R: The VA has approved and supports cloud-based conferencing tools: Cisco Webex, Microsoft Teams and Skype for Business.</td>
</tr>
<tr>
<td>2</td>
<td>2020.03.26</td>
<td>Ethics &amp; Reg</td>
<td>Trial Integrity</td>
<td>1) Changes to Protocol. It’s hard to know what to do. We don’t want to put big changes into place only to have it change back. 2) 18 Months from now—realistically what will visits in a hospital look like? Will there be any?</td>
<td>1) It is important for you to communicate with your funding PC, RIB, and DSMB regarding any potential changes to your protocols. 2) Be mindful of flow of communication within teams—make sure WG info is getting back to entire team.</td>
<td>Yes</td>
<td>Ethics &amp; Reg</td>
<td>Biostats</td>
</tr>
<tr>
<td>3</td>
<td>2020.03.26</td>
<td>Ethics &amp; Reg</td>
<td>Intervention Delivery</td>
<td>Pause to enrollment and/or changes to the way care was delivered – can we still make outcomes measureable at the end?</td>
<td>The delivery of care might change for some (virtual during this time). How much is telehealth going to influence the outcomes?</td>
<td>No</td>
<td>Biostats</td>
<td>CINDY COMMENT 4-30-20: With regards to sharing documents I would use either MS OneNote or MS Forms.</td>
</tr>
<tr>
<td>4</td>
<td>2020.03.26</td>
<td>Ethics &amp; Reg</td>
<td>Data Collection</td>
<td>1) All Research staff is working from home. 1a) There is inability to obtain enough VA laptops and VA cell phones. Restrictions still in place that don’t allow research staff to call subjects from personal cell phones. 1b) Small mail has also been affected—there is no one in the office to print and send mailings.</td>
<td>1) Can voice over IP or Skype be used? 2) Can encrypted email be used? Can VA research activities use My Healthevnet for email?</td>
<td>Yes</td>
<td>Data Sharing</td>
<td>Biostats</td>
</tr>
<tr>
<td>5</td>
<td>2020.03.26</td>
<td>Ethics &amp; Reg</td>
<td>Trial Integrity</td>
<td>Social isolation and anxiety may influence pain outcomes more than the regular intervention.</td>
<td>We don’t know how pain, in general, will be affected by the social isolation and anxiety caused by this pandemic.</td>
<td>No</td>
<td>Biostats</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>2020.04.03</td>
<td>Phen &amp; Outcomes</td>
<td>Data Collection</td>
<td>It was determined that COVID-19 will not have a major impact on the data collection plan for outcome data. Everyone on the call was collecting outcomes via remote data collection methods such as phone or online assessments. [Please note: DP20 and DP21 not in attendance.]</td>
<td>Investigators have in-person baseline visits or interventions that will be impacted. Address in Biostats or Implementation Science</td>
<td>Yes</td>
<td>Biostats</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>2020.04.03</td>
<td>Phen &amp; Outcomes</td>
<td>Outcomes</td>
<td>Self-report: Phenotype COVID testing and status.</td>
<td>Develop questions to phenotype this domain</td>
<td>Yes</td>
<td>Phen &amp; Outcomes</td>
<td></td>
</tr>
</tbody>
</table>
COVID-19 Impact on Pain Outcomes

• Pain is a complex, multidimensional, personal and social experience
  • Important to consider potential impacts of changes in socially relevant phenotyping variables
  • Pain Outcomes ↔ pandemic stressors, heightened anxiety, depression, isolation

• Phenotypes and Outcomes WG created a concise, PMC-harmonized COVID-19 outcome measure
  • Structured to be applicable to pain, but not directly attributable
  • Widespread adoption across trials
COVID-19 Outcome Assessment Instrument

7-item Self-report Instrument

Purpose: Measure impact of COVID-19 on covariates related to pain related outcomes

Domains

- Access to Health Care
- Social Support
- Finances
- Ability to meet Basic Needs
- Mental/Emotional Health
- Sick with COVID-19
- Self
- Others
Effects on PMC PCTs

- PMC PCT Status
- Pain Care Delivery
- Pain Care Outcomes
- Regulatory Approvals and Ethical Issues
- Participant Recruitment
- Sample Size and Analyses
- Benefit of Pragmatic Research
PMC PCT Status as of May, 2020

- 3 trials with continued implementation phase trial recruitment (with study protocol revision)
- 1 trial with temporary suspension of implementation phase trial recruitment
  - Continued follow up for previously enrolled participants
- 4 trials with temporary delay in start of implementation trial recruitment (with or without study protocol revision)
- 2 trials with temporary suspension of pilot study recruitment/completion
  - With continued follow up for previously enrolled participants
- 1 trial with temporary delay in start of pilot study recruitment
Effect on Pain Care Delivery

• Suspension of non-urgent/non-emergent face-to-face healthcare based on national, state, and facility-level directives

• Shift towards increased use of telehealth services across all of healthcare
  • Maintained access to some form of care during period of disruption for Veterans and Military Servicemembers
  • In one PCT assessing technology-assisted care delivery, the digitalization of “usual care” resulted in fewer differences between the treatment and control arms
Effect on Pain Care Outcomes

• Reduction in clinical encounters due to suspension of face-to-face care → potential for missing data that were planned for use in phenotyping and outcome analyses

• Some trial designs included multiple intervention components that were affected in varying ways, which we anticipate will yield potential alterations in the strength of treatment effects based on changes in delivery media
  • From patient perspective, these shifts might be positive or negative
Effect on Regulatory/Ethical Issues

• National research stoppages in both Veterans Health Administration and Defense Health Agency

• PMC PCTs reminded of responsibility to remain in timely and open communication with their institutional review boards and sponsoring agencies
  • Particularly in context of necessitated study protocol modifications, in accordance with regulations for human subjects research
Effect on Regulatory/Ethical Issues

• Informed Consent
  • Changes in consent processes involving the use of sophisticated virtual processes (e.g., receiving/sending encrypted email and smartphone screen capture of informed consent documents)

  • Changes in delivery media from internally hosted applications to third-party software applications

  • These modifications may make it difficult for some study participants to fully comprehend informed consent materials
Effect on Participant Recruitment

• Range of effects very likely
  • Decreased frequency of clinical encounters → decreased presence of EHR data used to identify eligible participants and recruit them as participants

• Some individuals may be more inclined to participate in PCTs as a function of limited availability of other pain interventions during pandemic period

• Increased stakeholder engagement through streamlined communication channels and interest in maintaining continuity of care
Effect on Sample Size and Analyses

- Downstream effects of changes in delivery interventions
  - Change in intervention → Affect on treatment fidelity → Reconsider study design
  - Moderating and mediating effects of COVID-19 and its impact on the fidelity of interventions, particularly usual care

- No simple solutions, no existing frameworks for study design and statistical analyses → A need for innovation and new approaches
Benefit of Pragmatic Research

• Main benefit of a pragmatic trial approach is the ability to “learn” within actual health environments through a bidirectional model of research and practice

• Minimizing the burden on research participants, investigators, and clinical care teams
  • Similar actions in the case of future disruptions to research activities

• Pragmatic nature affords the ability to respond quickly and adapt as the healthcare system adapts to disruption
What did we learn...

• A quick response, including detailed annotation of impacts and modifications, has been beneficial to track and communicate impacts of COVID-19 with important PMC stakeholders

• COVID-19 causes adaptation of clinical research in many unplanned ways
  • As intensity of pandemic ebbs and flows across the US, we can continue to expect varying levels of impact on multi-site PCTs
What did we learn...

- Pragmatic research is well suited to adapt to challenges that may arise that disrupt usual health care delivery
  - Some trials already examining methods well suited to transition to remote/telehealth methods

- Some challenged in reverse, where control arm begins to look like intervention arm

- All must consider treatment fidelity in modified study protocols and analyses of treatment effects
... and what’s still to learn

• Detailed challenges from PCTs
  • Implementation Science work group conducting serial questionnaire for qualitative analysis of impacts on PCTs over time

• PCTs are somewhat well positioned to respond to disruption – but how much disruption is too much? And how applicable are their findings if healthcare returns to its “pre-disruption” form?
Special Thanks

• Co-authors
  • Jacob Kean, PhD
  • Cynthia Brandt, MD MPH
  • Peter Peduzzi, PhD
  • Robert Kerns, PhD
  • Alison Davis, PhD
• PMC Project Managers
  • Amy Burns, JD
  • Mary Geda, MSN, RN
  • Lily Katsovich, MS, MBA
  • Norman Silliker

• PMC Operations Core
  • Margaret Antonelli
  • Allison Lee, MPH
  • Sakasha Taylor, MS
• PMC PIs and Study Teams
• Our Sponsor Organizations
• Our PCT Study Participants
• Today’s Attendees

• Amy Burns, JD
• Mary Geda, MSN, RN
• Lily Katsovich, MS, MBA
• Norman Silliker
Questions?

@PainMC3

@BCAColeman

Brian.Coleman@Yale.edu

www.painmanagementcollaboratory.org